Cargando…
Current treatment strategies for COVID-19
The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged suddenly at the end of 2019 and the disease came to be known as coronavirus disease 2019 (COVID-19). To date, there is no specific therapy established to treat COVID-19. Identifying effective treatments is u...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548951/ https://www.ncbi.nlm.nih.gov/pubmed/34664677 http://dx.doi.org/10.3892/mmr.2021.12498 |
_version_ | 1784590692190781440 |
---|---|
author | Han, Fabin Liu, Yanming Mo, Mei Chen, Juanli Wang, Cheng Yang, Yong Wu, Jibiao |
author_facet | Han, Fabin Liu, Yanming Mo, Mei Chen, Juanli Wang, Cheng Yang, Yong Wu, Jibiao |
author_sort | Han, Fabin |
collection | PubMed |
description | The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged suddenly at the end of 2019 and the disease came to be known as coronavirus disease 2019 (COVID-19). To date, there is no specific therapy established to treat COVID-19. Identifying effective treatments is urgently required to treat patients and stop the transmission of SARS-CoV-2 in humans. For the present review, >100 publications on therapeutic agents for COVID-19, including in vitro and in vivo animal studies, case reports, retrospective analyses and meta-analyses were retrieved from PubMed and analyzed, and promising therapeutic agents that may be used to combat SARS-CoV-2 infection were highlighted. Since the outbreak of COVID-19, different drugs have been repurposed for its treatment. Existing drugs, including chloroquine (CQ), its derivative hydroxychloroquine (HCQ), remdesivir and nucleoside analogues, monoclonal antibodies, convalescent plasma, Chinese herbal medicine and natural compounds for treating COVID-19 evaluated in experimental and clinical studies were discussed. Although early clinical studies suggested that CQ/HCQ produces antiviral action, later research indicated certain controversy regarding their use for treating COVID-19. The molecular mechanisms of these therapeutic agents against SARS-CoV2 have been investigated, including inhibition of viral interactions with angiotensin-converting enzyme 2 receptors in human cells, viral RNA-dependent RNA polymerase, RNA replication and the packaging of viral particles. Potent therapeutic options were reviewed and future challenges to accelerate the development of novel therapeutic agents to treat and prevent COVID-19 were acknowledged. |
format | Online Article Text |
id | pubmed-8548951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-85489512021-10-27 Current treatment strategies for COVID-19 Han, Fabin Liu, Yanming Mo, Mei Chen, Juanli Wang, Cheng Yang, Yong Wu, Jibiao Mol Med Rep Review The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged suddenly at the end of 2019 and the disease came to be known as coronavirus disease 2019 (COVID-19). To date, there is no specific therapy established to treat COVID-19. Identifying effective treatments is urgently required to treat patients and stop the transmission of SARS-CoV-2 in humans. For the present review, >100 publications on therapeutic agents for COVID-19, including in vitro and in vivo animal studies, case reports, retrospective analyses and meta-analyses were retrieved from PubMed and analyzed, and promising therapeutic agents that may be used to combat SARS-CoV-2 infection were highlighted. Since the outbreak of COVID-19, different drugs have been repurposed for its treatment. Existing drugs, including chloroquine (CQ), its derivative hydroxychloroquine (HCQ), remdesivir and nucleoside analogues, monoclonal antibodies, convalescent plasma, Chinese herbal medicine and natural compounds for treating COVID-19 evaluated in experimental and clinical studies were discussed. Although early clinical studies suggested that CQ/HCQ produces antiviral action, later research indicated certain controversy regarding their use for treating COVID-19. The molecular mechanisms of these therapeutic agents against SARS-CoV2 have been investigated, including inhibition of viral interactions with angiotensin-converting enzyme 2 receptors in human cells, viral RNA-dependent RNA polymerase, RNA replication and the packaging of viral particles. Potent therapeutic options were reviewed and future challenges to accelerate the development of novel therapeutic agents to treat and prevent COVID-19 were acknowledged. D.A. Spandidos 2021-12 2021-10-15 /pmc/articles/PMC8548951/ /pubmed/34664677 http://dx.doi.org/10.3892/mmr.2021.12498 Text en Copyright: © Han et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Han, Fabin Liu, Yanming Mo, Mei Chen, Juanli Wang, Cheng Yang, Yong Wu, Jibiao Current treatment strategies for COVID-19 |
title | Current treatment strategies for COVID-19 |
title_full | Current treatment strategies for COVID-19 |
title_fullStr | Current treatment strategies for COVID-19 |
title_full_unstemmed | Current treatment strategies for COVID-19 |
title_short | Current treatment strategies for COVID-19 |
title_sort | current treatment strategies for covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548951/ https://www.ncbi.nlm.nih.gov/pubmed/34664677 http://dx.doi.org/10.3892/mmr.2021.12498 |
work_keys_str_mv | AT hanfabin currenttreatmentstrategiesforcovid19 AT liuyanming currenttreatmentstrategiesforcovid19 AT momei currenttreatmentstrategiesforcovid19 AT chenjuanli currenttreatmentstrategiesforcovid19 AT wangcheng currenttreatmentstrategiesforcovid19 AT yangyong currenttreatmentstrategiesforcovid19 AT wujibiao currenttreatmentstrategiesforcovid19 |